Market Spotlight: Osteoarthritis and Osteoarthritis Pain
Market Spotlight: Osteoarthritis and Osteoarthritis Pain
$1,318.00
This Market Spotlight report covers the Osteoarthritis and Osteoarthritis Pain market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Osteoarthritis and Osteoarthritis Pain market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2019, there were 320.7 million prevalent cases of osteoarthritis (knee or hip) in adults aged 30 years and older worldwide, and forecasts that number to increase to 367.7 million prevalent cases by 2028.
- The global prevalence of osteoarthritis in adults aged 30 years and older is estimated to be 8.2%. The approved drugs in the osteoarthritis space focus on a wide variety of targets. The majority of these therapies are administered via the oral route, with the remainder being topical, intraarticular, and transdermal formulations.
- The majority of industry-sponsored drugs in active clinical development for osteoarthritis are in Phase II, with only one drug in the NDA/BLA phase.
- Therapies in development for osteoarthritis focus on a wide variety of targets. The largest proportion of pipeline drugs are administered via the intraarticular route.
- High-impact upcoming events for drugs in the osteoarthritis space comprise topline Phase II, Phase IIb, and Phase III trial results; an estimated CHMP opinion, and an expected PDUFA date.
- The overall likelihood of approval of a Phase I osteoarthritis and osteoarthritis pain asset is 10.2%, and the average probability a drug advances from Phase III is 50%. Drugs, on average, take 13.0 years from Phase I to approval in the osteoarthritis and osteoarthritis pain space, as well as in the overall rheumatology (non autoimmune) space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for osteoarthritis have been in the early and mid-phases of development, with 59% of trials in Phase I–II, and 41% in Phase III–IV.
- The US has a substantial lead in the number of osteoarthritis clinical trials globally. The UK leads the major European markets, while South Korea has the top spot in Asia.
- Clinical trial activity in the osteoarthritis space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for osteoarthritis, with 124 trials.
- Pfizer leads industry sponsors with the highest overall number of clinical trials for osteoarthritis.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Non-pharmacological treatment
9 Pharmacological treatment
10 Surgery
11 EPIDEMIOLOGY
14 MARKETED DRUGS
18 PIPELINE DRUGS
27 RECENT EVENTS AND ANALYST OPINION
27 Tanezumab for Osteoarthritis and Osteoarthritis Pain (March 25, 2021)
27 Tanezumab for Osteoarthritis and Osteoarthritis Pain (March 22, 2021)
28 GLPG1972 for Osteoarthritis and Osteoarthritis Pain (October 15, 2020)
30 Fasinumab for Osteoarthritis and Osteoarthritis Pain (August 18, 2020)
31 UBX0101 for Osteoarthritis and Osteoarthritis Pain (August 17, 2020)
32 Fasinumab for Osteoarthritis and Osteoarthritis Pain (August 5, 2020)
34 Otenaproxesul for Osteoarthritis and Osteoarthritis Pain (June 1, 2020)
36 KEY UPCOMING EVENTS
37 KEY REGULATORY EVENTS
37 Pfizer’s Tanezumab REMS Cannot Make Benefit-Risk Positive, US FDA Panel Says
37 Pfizer’s Tanezumab REMS Faces US FDA Doubts Heading Into Panel Review
37 Medipost Accelerates Global Push For Lead Stem Cell Therapy
39 PROBABILITY OF SUCCESS
40 LICENSING AND ASSET ACQUISITION DEALS
40 Samil Gets South Korean Rights To Biosplice’s Knee Arthritis Compound
40 LG Chem Expands Into Gene Therapy Via ICM Agreement
40 Merck KGaA Finds The Right Home For Disease-Modifying OA Agent In Novartis
41 REVENUE OPPORTUNITY
43 CLINICAL TRIAL LANDSCAPE
44 Sponsors by status
45 Sponsors by phase
46 Recent events
48 BIBLIOGRAPHY
49 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in prevalent cases of osteoarthritis (knee or hip), 2019–28
18 Figure 2: Overview of pipeline drugs for osteoarthritis in the US
18 Figure 3: Pipeline drugs for osteoarthritis, by company
19 Figure 4: Pipeline drugs for osteoarthritis, by drug type
19 Figure 5: Pipeline drugs for osteoarthritis, by classification
30 Figure 6: GLPG1972 for Osteoarthritis and Osteoarthritis Pain (October 15, 2020): Phase II – ROCCELLA
32 Figure 7: UBX0101 for Osteoarthritis and Osteoarthritis Pain (August 17, 2020): Phase II – Moderate to Severe Knee OA
34 Figure 8: Fasinumab for Osteoarthritis and Osteoarthritis Pain (August 5, 2020): Phase III – FACT OA1, Phase III – FACT OA2
35 Figure 9: Otenaproxesul for Osteoarthritis and Osteoarthritis Pain (June 1, 2020): Phase IIb – Dose-Ranging
36 Figure 10: Key upcoming events in osteoarthritis
39 Figure 11: Probability of success in the osteoarthritis and osteoarthritis pain pipeline
43 Figure 12: Clinical trials in osteoarthritis
43 Figure 13: Top 10 drugs for clinical trials in osteoarthritis
44 Figure 14: Top 10 companies for clinical trials in osteoarthritis
44 Figure 15: Trial locations in osteoarthritis
45 Figure 16: Osteoarthritis trials status
46 Figure 17: Osteoarthritis trials sponsors, by phase
LIST OF TABLES
12 Table 1: Prevalent cases of osteoarthritis (knee or hip), 2019–28
15 Table 2: Marketed drugs for osteoarthritis
20 Table 3: Pipeline drugs for osteoarthritis in the US
27 Table 4: Tanezumab for Osteoarthritis and Osteoarthritis Pain (March 25, 2021)
28 Table 5: Tanezumab for Osteoarthritis and Osteoarthritis Pain (March 22, 2021)
29 Table 6: GLPG1972 for Osteoarthritis and Osteoarthritis Pain (October 15, 2020)
30 Table 7: Fasinumab for Osteoarthritis and Osteoarthritis Pain (August 18, 2020)
31 Table 8: UBX0101 for Osteoarthritis and Osteoarthritis Pain (August 17, 2020)
33 Table 9: Fasinumab for Osteoarthritis and Osteoarthritis Pain (August 5, 2020)
34 Table 10: Otenaproxesul for Osteoarthritis and Osteoarthritis Pain (June 1, 2020)
41 Table 11: Historical global sales, by drug ($m), 2016–20
42 Table 12: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Small-Cell Lung Cancer (SCLC) 
Sign up to the